Monday, December 22, 2014 GILD cratered after news today. From Bloomberg: Gilead Sciences Inc. (GILD) shares sank after the biggest drug-benefit manager in the U.S. chose a pill from AbbVie Inc. (ABBV) to be the sole hepatitis C treatment approved for many patients, as insurers seek to rein in the rising cost of medicine. Express […]